Wedbush analyst Laura Chico upgraded Travere Therapeutics to Outperform from Neutral with a $30 price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TVTX:
- Travere Therapeutics price target lowered to $31 from $37 at Barclays
- Travere Therapeutics selloff on approval news overdone, says BofA
- Ligand’s partner Travere Therapeutics gets FDA accelerated approval of Filspari
- Travere Therapeutics announces FDA accelerated approval of Filspari
- Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy